Ms. Wasman has been a director of the Company since December 2017. Ms. Wasman was Chair of the Board from December 2017 to June 2024. Ms. Wasman was President, International & General Counsel and Corporate Secretary of Acorda Therapeutics, Inc., a publicly traded biopharmaceutical company, from October 2012 until December 2019, managing its international, legal, quality, IP and compliance functions. From January 2012 until October 2012, she was Acorda’s Chief, Strategic Development, General Counsel and Corporate Secretary, and from May 2004 until January 2012, she was Acorda’s Executive Vice President, General Counsel. Before joining Acorda, Ms. Wasman was with Schering-Plough Corporation, a global pharmaceutical company, for over eight years, holding various U.S. and international leadership positions, including Staff Vice President and Associate General Counsel. Ms. Wasman earned a J.D. from Harvard Law School and her undergraduate degree magna cum laude from Princeton University. Ms. Wasman is also a member of the board of directors of Rigel Pharmaceuticals, Inc., a publicly traded biopharmaceutical company. Ms. Wasman previously served on the board of Athersys, Inc., a publicly traded biopharmaceutical company, Cytovia Therapeutics, a private company, and NewYorkBIO (including its Executive Committee).
What is Jane Wasman's net worth?
The estimated net worth of Jane Wasman is at least $176.93 thousand as of May 30th, 2025. Wasman owns 30,400 shares of SELLAS Life Sciences Group stock worth more than $176,928 as of March 11th. This net worth approximation does not reflect any other assets that Wasman may own. Learn More about Jane Wasman's net worth.
How do I contact Jane Wasman?
Has Jane Wasman been buying or selling shares of SELLAS Life Sciences Group?
Jane Wasman has not been actively trading shares of SELLAS Life Sciences Group during the last quarter. Most recently, on Friday, May 30th, Jane Wasman bought 20,000 shares of SELLAS Life Sciences Group stock. The stock was acquired at an average cost of $1.69 per share, with a total value of $33,800.00. Following the completion of the transaction, the director now directly owns 30,400 shares of the company's stock, valued at $51,376. Learn More on Jane Wasman's trading history.
Who are SELLAS Life Sciences Group's active insiders?
Are insiders buying or selling shares of SELLAS Life Sciences Group?
During the last twelve months, SELLAS Life Sciences Group insiders bought shares 3 times. They purchased a total of 93,400 shares worth more than $149,406.00. The most recent insider tranaction occured on November, 19th when Director Katherine Bach Kalin bought 63,400 shares worth more than $100,806.00. Insiders at SELLAS Life Sciences Group own 1.2% of the company.
Learn More about insider trades at SELLAS Life Sciences Group. Information on this page was last updated on 11/19/2025.
